Chen Xin Pharmaceutical Co., Ltd. is a comprehensive chemical manufacturer. At present, the company is a national high-tech enterprise, a pharmaceutical expert unit specially invited by Taishan scholars in Shandong postdoctoral research mobile station, Shandong Enterprise Technology Center and Shandong Antibiotic Engineering Technology Research Center. It has successively won the honors of Industrialization Support Fund of National Development and Reform Commission, Technology Innovation Fund of Science and Technology Enterprises of Ministry of Science and Technology, and China Patent Shandong Star Enterprise. In May of 20 1 1, the trademark "Chen Xin" was recognized as "China Famous Trademark" by the State Administration for Industry and Commerce, and it was also selected as the best industrial enterprise in China pharmaceutical R&D product line in 20 1 and the most valuable enterprise in China pharmaceutical industry in 201. Adhering to the corporate philosophy of "innovation and innovation, honesty and trustworthiness", the company insists on taking science and technology as the guide, surviving by quality and developing by innovation, and has embarked on a road of scientific and technological innovation. It has successively invested and built 15 production workshops, a modern animal laboratory building and a large-scale elevated three-dimensional warehouse in the First Industrial Park of the Development Zone. On June 20 10, the foundation stone was laid for Chen Xin No.2 industrial park, which accelerated the Chen Xin pharmaceutical industry to March into new products with great technical difficulties, long life cycle and high added value. The company can produce nearly 400 specifications of products in eight dosage forms, such as large infusion (non-PVC soft bag infusion, plastic bottle infusion and glass bottle infusion), water injection, freeze-dried powder injection, tablets, ointments, eye drops, capsules and small bulk drugs. Among them, infusion was rated as a famous brand product in Shandong Province, and the output of infusion products ranked first in domestic single factory, and the output of water needles ranked first in Shandong Province. Chen Xin Pharmaceutical is committed to ensuring and improving patients' quality of life and health, and is committed to independent research and development and production of drugs that can fill domestic gaps. We spend 6% of our sales revenue on scientific research and development every year, and have successively established long-term cooperative relations with China Pharmaceutical University, Shenyang Pharmaceutical University, Shandong University, Shandong Academy of Medical Sciences, Shandong Institute of Pharmaceutical Industry, Institute of Pharmacy of China Academy of Sciences, Academy of Military Medical Sciences and other scientific research institutes, successfully embarked on a road of "joint innovation of production, learning and research", established a one-stop development system from market research, development design to trial production, and formed a research generation. The new products cover cardiovascular and cerebrovascular diseases, antibacterial, antiviral and anticancer diseases 100 varieties. Among them, adefovir dipivoxil (raw materials and tablets) independently researched and developed by Chen Xin Pharmaceutical was awarded the national first-class new drug certificate, won the first prize of scientific and technological progress in Shandong Province, and was supported by the Ministry of Science and Technology and provincial and municipal scientific and technological innovation funds. The successful development of the drug is a major breakthrough in the field of independent research and development of hepatitis B drug treatment in China. It is of great significance to promote the technological progress of China's pharmaceutical industry, accelerate the industrialization of China's pharmaceutical high-tech achievements, and improve the technological innovation ability and international competitiveness of China's biomedical industry. This will also be the engine for Chen Xin brand to upgrade again. Chen Xin Pharmaceutical attaches great importance to product quality management. We adhere to the quality management policy of "quality first, prevention first" and the quality management concept of "drugs are rich because of quality, and the industry is proud of brands", and have established a detailed and effective quality assurance system. The general manager is fully responsible for the product quality, and the quality assurance department of the company sends quality personnel to each workshop to supervise and guide the production quality management of the workshop, so as to implement the quality veto right. Each workshop should set up process monitoring points at production posts to strictly control quality inspection and supervision. At present, all the products of the company have passed the GMP certification and three-system certification of the Certification Center of the US Food and Drug Administration, and have been rated as the demonstration unit of quality management and on-site management in Shandong Province by the Shandong Enterprise Federation. During the Twelfth Five-Year Plan period, Chen Xin Pharmaceutical will continue to focus on scientific and technological innovation, raise funds by introducing strategic investors, listing, joint venture, capital increase and other forms, increase investment in new product research and development, improve the technical content of new products, and strive to achieve the grand goal of sales revenue of 654.38 billion yuan and profits and taxes of 2 billion yuan in 2065.438+05, and make greater contributions to the development of pharmaceutical industry in China!